

201415028B

---

厚生労働科学研究費補助金  
難治性疾患等実用化研究事業

抗菌活性・創修復作用を有する新規ペプチドを用いた  
遺伝的早老症患者の難治性潰瘍治療薬の開発

平成25年度～26年度 総合研究報告書

---

研究代表者 中神 啓徳  
平成27(2015)年 3月



---

厚生労働科学研究費補助金  
難治性疾患等実用化研究事業

抗菌活性・創修復作用を有する新規ペプチドを用いた  
遺伝的早老症患者の難治性潰瘍治療薬の開発

平成25年度～26年度 総合研究報告書

---

研究代表者 中神 啓徳  
平成27(2015)年 3月

# 目 次

## I. 総括研究報告

抗菌活性・創修復作用を有する新規ペプチドを用いた遺伝的早老症患者の難治性潰瘍治療薬の開発 中神 啓徳	1
---	---

II. 研究成果の刊行に関する一覧表	4
--------------------	---

## III. 研究成果の刊行物・別刷

抗菌活性・創修復作用を有する新規ペプチドを用いた遺伝的早老症患者の難治性潰瘍治療薬の開発

研究代表者 中神 啓徳 大阪大学大学院連合小児発達学研究所 寄附講座教授

**[研究要旨]**

新規ペプチド SR-0379 は血管新生促進作用等による創傷治癒効果と膜透過性変化による抗菌作用を併せ持ち、難治性皮膚潰瘍治療を目指した外用薬開発を目指す薬剤である。ウエルナー症候群に多く合併する慢性皮膚潰瘍への適応が目標とし、将来的には糖尿病性潰瘍・褥瘡などへの適応の拡大を視野に入れる。医師主導治験に向けた非臨床試験を進める。ラット全層欠損モデルでの創傷治癒促進作用、薬物動態試験(LC/MS/MS)、毒性試験（ラット 4 週間反復毒性試験）、安全性薬理試験（中枢神経・呼吸・心血管系）、刺激性・感作性試験（ウサギ皮膚累積刺激性試験、モルモット皮膚感作性試験）が終了し、CMC として早期探索的な臨床試験に必要な治験薬 GMP での原薬・製剤化を行い、SR-0379 0%, 0.02%, 0.1%, 0.25%, 0.5% のスプレー製剤の製造を終了した。また、PMDA との事前面談で治験体制の確認を行った後、外部フェーズ I 施設に委託して皮膚刺激性試験を計画し、審査評価委員会での承認後に治験届を提出した。PMDA への回答終了後に 11 月に健康人 20 名に対してパッチテスト（48 時間 closed patch test）を施行した。塗布部位の軽度（±）な紅班が散見されたが、局所部位をはじめバイタルサイン、臨床検査値、心電図検査においても特段の問題となる所見は見られなかった。翌年以降の患者での臨床試験に向けて、薬事戦略相談・事前面談を行い、実施計画書などの作成を行った。

**分担研究者**

楽木 宏実	大阪大学大学院医学系研究科・教授
富岡 英樹	アンジェスMG・研究員
渡辺 元	アンジェスMG・研究員
横手幸太郎	千葉大学大学院医学研究科・教授
三木 哲郎	京都大学大学院医学系研究科・特任教授

特に QOL の改善から新しい治療法が求められている。

我々が同定した新規抗菌性ペプチド AG30 を用いた難治性皮膚潰瘍治療薬の開発は、早期探索型臨床試験拠点のシーズとし選定されたことを契機に、医師主導型治験あるいは将来的な企業への導出を念頭におき改変体を作成し、AG30/5C ペプチドが血清によって分解される代謝産物の機能解析から、20 残基のアミノ酸で一部 D 体にアミノ酸を置換した低コストで活性のあるペプチドの作成に成功した（SR ペプチド）。このペプチドを用いた同疾患への医師主導型治験を計画している。

**A. 研究目的**

創に対する治療法として、創傷治癒を促進するための湿潤環境を作る湿潤療法が提唱されている。他方、創部では皮膚のバリアー機構が破綻しているために種々の細菌が繁殖することが多く、創の治りに関与しない汚染あるいは繁殖（コロニゼーション）の状態か、又は創の治癒を遅延させる感染の状態かを正確に見極めて、適切な治療を行うことが重要とされる。

難治性皮膚潰瘍では局所感染兆候（発熱・発赤・腫脹・疼痛）の判定が困難なことが多く、その感染に至る前段階（クリティカルコロニゼーション）での見極めが難しい。特にウエルナー患者での皮膚潰瘍は圧のかかる部位に好発するため創傷被覆材が用いられることが多い。難治性潰瘍患者では

**B. 研究方法**

医師主導治験に向けた非臨床試験を進める。すで、ラット全層欠損モデルでの創傷治癒促進作用、各種細菌に対する抗菌活性、CMC（原薬の分析・安定性）、薬物動態試験(LC/MS)、ウサギ皮膚一次刺激性試験、遺伝毒性試験（非 GLP）、ラット 2 週間反復毒性試験（非 GLP）、毒性試験（ラット 4 週間反復毒性試験）、安全性薬理試験（中枢神経・呼吸）、刺激性・感作性試験（ウサギ皮膚累積刺激性試験、モルモット皮膚感作性試験）が終了しており、平成 26 年度はサルでの安全性薬理試験（循環系）を遂行した。

CMC は治験薬 GMP での原薬・製剤の予備検討が終了しており、平成 26 年度は治験薬の原薬製造・製剤化を行った。また、SR-0379 の作用メカニズムの検討として細胞内情報伝達系の解析も行なった。臨床試験に向けた書類整備（手順書・治験薬概要書・実施計画書・症例報告書・患者説明文書）を進め、治験審査評価委員での承認、PMDA への治験届提出後に健常人 20 名に対するパッチテストを行った。

#### （倫理面への配慮）

すべての基礎研究は事前に動物実験プロトコールなどが大阪大学大学院医学系研究科で承認された上で遂行した。

本研究のすべての動物実験は下記の国のガイドライン・法律などを遵守し、実施する。

- ・ 「動物の愛護および管理に関する法律」（昭和 48 年法律第 105 号）
- ・ 「研究機関などにおける動物実験等の実施に関する基本指針」（平成 18 年度厚生労働省告示第 71 号）

非臨床試験は、非臨床試験は薬事法の「医薬品の安全性に関する非臨床試験の実施の基準に関する省令」に則り GLP 基準で遂行する。

医師主導治験は、「医薬品の臨床試験の実施に関する基準（Good Clinical Practice: GCP）」に準拠し、適切な説明に基づく被験者の同意の確保、及び被験者の人権保護に配慮することにより実施される。臨床試験は改正薬事法に従い施行する。また、実施医療機関の治験審査委員会の審査、承認を経て、自ら治験を実施しようとする者から厚生労働大臣宛てに治験計画届書が提出される。

### C. 研究結果

医師主導型治験に向けて PMDA との薬事戦略事前面談を 2013 年 6 月 5 日（水）、非臨床試験項目の充足性に関する対面助言を 10 月 3 日（木）に行い、その方針に従って研究を遂行した。薬効薬理試験・薬物動態試験に加えて、GLP 試験での、ウサギ皮膚刺激性試験、モルモット皮膚感作性試験、ラット反復毒性試験、安全性薬理試験（呼吸系系・中枢性）を行い、感作性試験以外は特筆する所見を認めなかった。平成 26 年度にサルを用いた循環器系の安全性薬理試験を行ったが、特に問題を認めなかった。一方、CMC（原薬・製剤化）に関しては、ペプチド合成を American Peptide 社で予備検討を行ない規格値の設定を行なった。製剤化に関しては、ナガセ医薬品で予備検討を行ない、容器の

選定（スプレー製剤）およその機能評価をし、安定性試験を行なった。治験薬 GMP での書類整備として手順書・製品標準書の作成、体制整備・品質管理に関する教育訓練受講などの準備を行い、平成 26 年度にはこの予備検討を元にして、治験薬 GMP で American Peptide 社で治験薬の合成を行い、その後ナガセ医薬品で製剤化を行い、第 1 相および第 1/2a 相に必要な製剤合成を終了した。また、SR-0379 の細胞内情報伝達系の解析も並行して行い、インテグリンシグナルの FAK あるいはその下流の PI-3kinase がヒト線維芽細胞で活性化され、細胞増殖・遊走を促すことが分かり、SR-0379 の創修復作用のメカニズムが明らかとなった。

上記試験をもって、PMDA 薬事戦略相談対面助言で確認した患者での初期評価試験に必要な非臨床試験をすべて実施終了し、製剤も完成したため患者への投与の臨床治験の開始が可能となった。

臨床試験に関しては、第 1 相試験として健常人 20 名を対象とした皮膚刺激性試験（パッチテスト）を信濃坂クリニックに委託して行った。結果、特に刺激性を認めず次相の患者への試験へと進むこととなった。第 1/2a 相に関しては、PMDA 薬事戦略相談を 12 月に行い、3 月に対面助言を実施して試験デザインを決定した。先行して行っていた AG30/5C の臨床研究も 2 例の皮膚潰瘍患者に対して投与を行った。安全性評価としては特に因果関係のある有害事象は認めなかった。有効性については潰瘍面積の縮小効果、投与期間中の菌量の減少効果が認められた。次年度の患者での臨床試験に向けた準備として、分担研究者の横手教授を中心にウエルナー症候群の患者会で本研究の取り組みを紹介し、患者への情報提供を積極的行なった。

### D. 考察

医師主導治験として、自ら開発した化合物を原薬・製剤化から取り組んでおり、治験薬 GMP としての書類整備後に初期評価試験までの治験薬の製造を完了した。また、非臨床試験に関しても PMDA での対面助言で充足性を確認した試験を終了することができた。臨床試験においても、健常人での皮膚刺激性試験（パッチテスト）を終了した。次年度以降で患者での臨床治験を開始する予定である。

### E. 結論

早老症に合併する難治性皮膚潰瘍の新規治療薬開発を目指して、非臨床試験・CMC・臨床試験（健康人に対するパッチテスト）を終了した。今後、皮膚潰瘍患者での評価へと進む予定である。

#### F. 健康危険情報

特になし

#### G. 研究発表

Tomioka H, Nakagami H, Tenma A, Saito Y, Kaga T, Kanamori T, Tamura N, Tomono K, Kaneda Y, Morishita R. Novel Anti-Microbial peptide, SR-0379, Accelerates Wound Healing via the PI3 Kinase/Akt/mTOR Pathway. PLOS ONE 2014;9:e92597.

Tomioka H, Nakagami H, Sano T, Takafuji K, Takashima S, Kaneda Y, and Morishita R, Development of LC-MS/MS quantification of the novel antimicrobial peptide, SR-0379, and its pharmacokinetics in rats. *Immun, Endoc. & Metab. Agents in Med.* 2014;14:26-31

#### 2. 学会発表

中神 啓徳「Clinical Application of Novel Angiogenic Peptide for Severe Ischemic Ulcer; from Discovery to Drug Development from Academia」第78回日本循環器学会学術集会、2014. 3. 23、東京<シンポジウム>

Hironori Nakagami「A Novel Anti-microbial Peptide, SR-0379, Accelerated Wound Healing; Toward Clinical Application」The 18th International Vascular Biology Meeting、2014. 4. 14、京都<シンポジウム>

中神 啓徳「新規抗菌性ペプチドの同定・改良による難治性皮膚潰瘍外用薬の開発」第11回DIA日本年会、2014. 11. 17、東京<シンポジウム>

中神 啓徳「新規機能性ペプチドの発見から臨床開発に向けて」メディカルジャパン 2015 大阪、2015. 2. 4、大阪<口演>

中神 啓徳「皮膚潰瘍治療薬の開発研究への道程」第2回ヤング・サイエンティスト・シンポジウム、2015. 1. 24、東京<口演>

#### 3. 新聞報道

「傷治し感染を抑える化合物を開発、大阪大、皮膚潰瘍に。」2014.3.28. 毎日新聞、中日新聞、西日本新聞、大分合同新聞他

#### H. 知的財産権の出願・登録状況

- 1) 名称：血管新生誘導剤及びそれに用いられるポリペプチド

出願番号：特願 2007-29945

出願日：平成19年2月9日

PCT JP2008/052022

発明者：中神啓徳、西川智之、金田安史、森下竜一、前田明人、田村奈緒

- 2) 名称：新規ポリペプチドおよびそれを有効成分

として含有する抗菌剤

出願番号：特願 2007-29920

出願日：平成19年2月9日

PCT JP2008/052020

発明者：中神啓徳、西川智之、金田安史、朝野和典、前田明人、田村奈緒

出願人：大阪大学およびジェノメディア(株)

- 3) 名称：血管内皮細胞増殖促進遺伝子

出願番号：特願2004-081688

出願日：平成16年3月19日、

PCT/JP2005/004832

発明者：西川智之、中神啓徳、金田安史

出願日：2000年10月5日

研究成果の刊行に関する一覧表  
雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Nakagami H</u> , Nishikawa T, Tamura N, Maeda A, Hibino H, Mochizuki M, Shimosato T, Moriya T, Morishita R, Tamai K, Tomono K, Kaneda Y	Modification of a Novel Angiogenic Peptide, AG30, for the Development of Novel Therapeutic Agents.	J Cell Mol Med	16(7)	1629-1639	2012
Tomioka H, <u>Nakagami H</u> , Tenma A, Saito Y, Kaga T, Kanamori T, Tamura N, Tomono K, Kaneda Y, Morishita R	Novel Anti-Microbial peptide, SR-0379, Accelerates Wound Healing via the PI3 Kinase/Akt/mTOR Pathway.	PLOS ONE	9(3)	e92597	2014
Tomioka H, <u>Nakagami H</u> , Sano T, Takafuji K, Takashima S, Kaneda Y, and Morishita R,	Development of LC-MS/MS quantification of the novel antimicrobial peptide, SR-0379, and its pharmacokinetics in rats.	Immun,Endoc.&M etab. Agents in Med.	14	26-31	2014

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

研究成果の刊行物・別刷





# Novel Anti-Microbial Peptide SR-0379 Accelerates Wound Healing via the PI3 Kinase/Akt/mTOR Pathway

Hideki Tomioka<sup>1,2</sup>, Hironori Nakagami<sup>3\*</sup>, Akiko Tenma<sup>2</sup>, Yoshimi Saito<sup>2</sup>, Toshihiro Kaga<sup>2</sup>, Toshihide Kanamori<sup>2</sup>, Nao Tamura<sup>2</sup>, Kazunori Tomono<sup>5</sup>, Yasufumi Kaneda<sup>4</sup>, Ryuichi Morishita<sup>1\*</sup>

**1** Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, Japan, **2** AnGesMG, Inc., 7-7-15 Saito Bio-Incubator, Ibaraki, Osaka, Japan, **3** Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, 2-1 Yamada-oka, Suita, Osaka, Japan, **4** Division of Gene Therapy Science, Osaka University Graduate School of Medicine, School of Child Development, 2-1 Yamada-oka, Suita, Osaka, Japan, **5** Division of Infection Control and Prevention, Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, Japan

## Abstract

We developed a novel cationic antimicrobial peptide, AG30/5C, which demonstrates angiogenic properties similar to those of LL-37 or PR39. However, improvement of its stability and cost efficacy are required for clinical application. Therefore, we examined the metabolites of AG30/5C, which provided the further optimized compound, SR-0379. SR-0379 enhanced the proliferation of human dermal fibroblast cells (NHDFs) via the PI3 kinase-Akt-mTOR pathway through integrin-mediated interactions. Furthermore SR-0379 promoted the tube formation of human umbilical vein endothelial cells (HUVECs) in co-culture with NHDFs. This compound also displays antimicrobial activities against a number of bacteria, including drug-resistant microbes and fungi. We evaluated the effect of SR-0379 in two different wound-healing models in rats, the full-thickness defects under a diabetic condition and an acutely infected wound with full-thickness defects and inoculation with *Staphylococcus aureus*. Treatment with SR-0379 significantly accelerated wound healing when compared to fibroblast growth factor 2 (FGF2). The beneficial effects of SR-0379 on wound healing can be explained by enhanced angiogenesis, granulation tissue formation, proliferation of endothelial cells and fibroblasts and antimicrobial activity. These results indicate that SR-0379 may have the potential for drug development in wound repair, even under especially critical colonization conditions.

**Citation:** Tomioka H, Nakagami H, Tenma A, Saito Y, Kaga T, et al. (2014) Novel Anti-Microbial Peptide SR-0379 Accelerates Wound Healing via the PI3 Kinase/Akt/mTOR Pathway. PLoS ONE 9(3): e92597. doi:10.1371/journal.pone.0092597

**Editor:** Ganesh Chandra Jagetia, Mizoram University, India

**Received:** October 5, 2013; **Accepted:** February 24, 2014; **Published:** March 27, 2014

**Copyright:** © 2014 Tomioka et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was supported by a Health Labour Sciences Research Grant in Japan, and partially funded by AnGes MG. No additional funding was received for this study. Hideki Tomioka, Akiko Tenma, Yoshimi Saito, Toshihiro Kaga, Toshihide Kanamori and Nao Tamura are employees of AnGes MG. The funder provided support in the form of salaries for authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "Author Contributions" section.

**Competing Interests:** Ryuichi Morishita is an Editorial Board Member of PLOS ONE. Ryuichi Morishita is a founder of AnGes MG, and a stockholder. AnGes MG has the following patent licenses of AG30/5C (PCT/JP2008/052020: Novel polypeptide and antibacterial agent comprising the same as active ingredient) and SR-0379 (PCT/JP2010/058838: Polypeptides and antibacterial or antiseptic use of same). Hideki Tomioka, Akiko Tenma, Yoshimi Saito, Toshihiro Kaga, Toshihide Kanamori and Nao Tamura are employees of AnGes MG. Department of clinical gene therapy is financially supported by AnGes MG, Novartis, Shionogi, Boehringer, and Rohto. Division of Vascular Medicine and Epigenetics is financially supported by Bayel. This study is partially supported by the fund of AnGes MG. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

\* E-mail: nakagami@gts.med.osaka-u.ac.jp (HN); morishit@cgt.med.osaka-u.ac.jp (RM)

## Introduction

Antimicrobial peptides are produced by multicellular organisms as a defense mechanism against competing pathogenic microbes [1]. Currently, more than 1,200 antimicrobial peptides have been discovered in animals and plants [2]. In addition to their antimicrobial functions, some peptides, such as LL-37, are known to have other functions. For example, LL-37 is chemotactic for monocytes, T cells, neutrophils and mast cells and also stimulates mast cell histamine release and angiogenesis [3]. These observations have led to the development of a therapeutic concept using antimicrobial peptides as multifunctional effector molecules to prevent infection directly and to promote wound healing in various ulcers. Indeed, many researchers have tried to develop antimicrobial peptides for topical use and systemic application [4] [5]. Before these peptides can be used in clinical applications, several improvements must be made, including 1) increased

stability, 2) reduced cytotoxicity and 3) improved antimicrobial activity [6]. To improve the stability of antimicrobial peptides, converting amino acids from L to D conformations has been attempted [7]. Antimicrobial peptides are usually positively charged, between 12 and 100 amino acids in length and form amphipathic structures. The production of shorter analogs may also resolve the cost issue for clinical applications.

We previously developed an antimicrobial peptide named AG30 (angiogenic peptide 30) that contained 30 amino acids and possessed both angiogenic and antibacterial functions [8] [9]. For clinical application in the treatment of drug-resistant ulcers, we have modified AG30 to enhance its angiogenic activity, broaden its antibacterial function, enhance its stability and reduce its cost. In this study, we have demonstrated the production of a stable, shorter peptide, SR-0379, that contains twenty amino acids, including one lysine residue that has been converted to D-lysine. This peptide exhibited antimicrobial activities against a

number of bacteria, including drug-resistant bacteria, and induced the proliferation, tube formation, migration and contraction of human dermal fibroblast cells.

Treatment with SR-0379 significantly accelerated wound healing in a skin ulcer model. In the intracellular mechanism of wound healing, we focused on the PI3K/Akt/mTOR pathway. It has been reported that Akt/mTOR activation, by the ablation of Pten and Tsc1, dramatically increased epithelial cell proliferation, migration, and cutaneous wound healing, while pharmacological inhibition of mTOR with rapamycin delays wound closure [10]. Indeed, SR-0379 would activate the Akt/mTOR pathway which lead to accelerate wound healing. Further application of SR-0379 might provide a new therapeutic option to treat various ulcers, such as diabetic ulcers and severe burns.

## Results

### Design of SR-0379

For use in clinical applications, we first modified AG30 to improve its stability and reduce its cost. To perform the lead-to-drug-candidate optimization, various approaches to improve stability were evaluated. The metabolic stability of AG30/5C was evaluated by using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Figure S1 in File S1). The major metabolites were 20 amino acids (aa), 18 aa and 17 aa, which overlap the N terminus AG30/5C and 12 aa in the middle of AG30/5C (Fig. 1A). The metabolites of AG30/5C were cleaved by endopeptidases and exopeptidase at multiple sites, with most cleavage sites present in the C-terminus. Those metabolites were synthesized (Fig. 1B), and their proliferation in HUVECs, tube formation in co-culture of HUVECs and NHDFs and antibacterial activities against *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus aureus* were evaluated. Treatment with the 20-aa peptide (SR-0007) yielded significant increases in proliferation of HUVECs (Fig. 1C), whereas other metabolites did not have significant effects (data not shown). The stimulatory effects of SR-0007 were equivalent to the effects of AG30/5C (Fig. 1C). Furthermore, the treatment with SR-0007 (10 µg/ml) induced tube form in co-culture of HUVECs and NHDFs with the same level of AG30/5C (Fig. 1D). SR-0007 exhibited similar antibacterial activities against *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus aureus* as AG30/5C (Table 1). These results revealed that SR-0007, which consists of 20 amino acids, is a potent candidate metabolite like AG30. However, SR-0007 was rapidly degraded by rat and human sera at 37°C (Figure 1E). Therefore, we further modified SR-0007 to improve its stability. The lysine in SR-0007 was replaced with D-form lysine, and the resulting compound was named SR-0379. As shown in Fig. 1E, the stability of SR-0379 was significantly improved, suggesting that SR-0379 might be resistant to the actions of known natural peptidases [11].

### Antibacterial activity of SR-0379 in drug-resistant/sensitive strains


We examined the antibacterial effects of AG30/5C, SR-0007 and SR-0379 against *E. coli*, *P. aeruginosa* and *S. aureus* (Table 1). Importantly, SR-0379 exhibited more potent antibacterial activity against *E. coli* compared to the original SR-0007 peptide, whereas the minimal inhibitory concentration (MIC) of SR-0379 against *P. aeruginosa* was equivalent to that of SR-0007. A number of strains were then evaluated for their sensitivities to SR-0379 (Table 2). SR-0379 demonstrated potent antibacterial activity against gram-positive and gram-negative aerobes and anaerobes. Additionally, SR-0379 exhibited antibacterial effects against fungi such as

*Candida krusei*. Notably, the antimicrobial spectrum of SR-0379 is broader than the spectra for antibiotics such as chloramphenicol or amphotericin B (Table 2) failed to exhibit an inhibitory activity against fungi or bacteria, respectively. Furthermore, we tested the antibacterial effects of SR-0379 on antibiotic-resistant/sensitive strains for use in clinical applications. Unexpectedly, SR-0379 exhibited similar inhibitory effects on various antibiotic-resistant strains, such as methicillin-resistant *S. aureus* (MRSA) and multidrug-resistant *Acinetobacter baumannii*, compared to the sensitive strains (Table 3). As antimicrobial peptide functional mechanisms are related to the disruption of the bacterial membrane [12], SR-0379 may exhibit potent antibacterial effects against other antibiotic-resistant strains.

### Cellular functions of SR-0379 and its molecular mechanisms

We investigated the effects of SR-0379 on the proliferation, migration and contraction capacity of neonatal normal human dermal fibroblasts (NHDFs) and examined the angiogenic activity of HUVECs in co-culture with NHDFs. In the proliferation assay, the treatment with SR-0379 (1, 3 and 10 µg/ml) resulted in significant increase in the proliferation of fibroblasts in a dose-dependent manner (Fig. 2A). Whereas Normal Human Epidermal Keratinocytes (NHEKs) were treated with SR-0379 (1, 3 and 10 µg/ml), SR-0379 did not affect cell proliferation (Figure S2 in File S1). Similarly, in the tube formation assay, the treatment with SR-0379 (0.5, 2.5 and 10 µg/ml) significantly induced tube formation of HUVECs in co-culture with NHDFs as angiogenic activity (Fig. 2B). In the migration assay, the treatment with SR-0379 (1 and 10 µg/ml) also resulted in significant increases in migration activity (Fig. 2C). In the fibroblast-collagen-matrix contraction assay, the treatment with SR-0379 (1, 3, 10 and 30 µg/ml) significantly induced contraction as a measure of wound healing activity (Fig. 2D). When compared to the activities of FGF2 (0.3 µg/ml), the contraction activity of SR-0379 (30 µg/ml) was more potent, while the other activities were equivalent or less potent in SR-0379. Interestingly, the treatment with SR-0379 significantly increased the mRNA expression of interleukin-8 (IL-8) which was attenuated with pretreatment of Wortmannin (PI3kinase inhibitor, 100 nM) (Figure S3A in File S1). Similarly, the treatment with SR-0379 increased IL-8 protein expression in a dose dependent manner (Figure S3B in File S1).

What are the molecular mechanisms of these actions of SR-0379? The phosphorylation effects of SR-0379 on FAK at Tyr397 and Tyr925 and on Akt at Ser473 were examined in NHDFs. As shown in Fig. 3A, treatment with SR-0379 (10 µg/ml) increased the phosphorylation of FAK Tyr397 and Akt Ser473 but not of FAK Tyr925 after 30 minutes, similar to the well-known antimicrobial peptide LL-37. The treatment with SR-0379 at doses of 0.3 to 10 µg/ml also significantly increased the phosphorylation of FAK Tyr397 and Akt Ser473 (Fig. 3B). The involvement of integrins was also tested in NHDFs. Pretreatment with RGD peptide (30, 100 and 300 µM), a small-molecule integrin antagonist, inhibited the activation of FAK and Akt induced by SR-0379 (Fig. 3C). Wortmannin (100 nM) and Rapamycin (1 nM) also inhibited the activation of Akt induced by SR-0379 (Fig. 3D, 3E). The treatment with SR-0379 (10 µg/ml) resulted in a significant increase in cell proliferation of fibroblast, whereas Akt knockdown using siRNA attenuated SR-0379-induced cell proliferation (Figure 3F and Figure S4A in File S1). Similarly, an inhibitor of Akt by Akt inhibitor IV (1 µM) also attenuated SR-0379-induced cell proliferation (Figure S4B in File S1). These results demonstrated the importance of Akt pathway in the effect of SR-0379.



**Figure 1. Lead optimization from the angiogenic peptide AG30/5C.** A) Major metabolites of AG30/5C determined by MALDI-TOF MS. The parent compound (AG30/5C) was incubated with rat serum *in vitro* 60 minutes. The metabolites were identified by comparison with the pre-incubation peptide. B) Sequences and net charges of AG30/5C and AG30/5C-derived peptides (SR-0007 and SR-0379). The lysine (K) of SR-007 was replaced with D-lysine in SR-0379. C) Effect of AG30/5C (10 µg/ml) and SR-0007 (10 µg/ml) on HUVECs proliferation. N=3 per group. \*P<0.05 vs. control. D) Effect of AG30/5C (10 µg/ml) and SR-0007 (10 µg/ml) on tube formation. The formation of capillary-like structures was observed in co-cultures of HUVECs and NHDFs. N=5-12 per group. \*P<0.05 vs. control. E) Stability of SR-0007 and SR-0379 in rat and human sera. SR-0007 and SR-0379 were quantified before or after incubation *in vitro* with rat and human sera for either 3 or 10 minutes. N=2. doi:10.1371/journal.pone.0092597.g001

**Acceleration of wound healing by SR-0379 *in vivo***

To evaluate the potential use of SR-0379 in clinical practice, a full-thickness wound model with a skin flap was employed in a streptozotocin-induced diabetic rat model. On day 2, the wound area was quickly and significantly reduced in the SR-0379 (0.2 mg/ml) group but not in the saline and FGF2 groups (Fig. 4A, 4B). As shown in Fig. 4A, the color of the wound surface on day 6 was red (bloody) in the SR-0379 treatment group. In contrast, the color of the wound surface was still dark with necrotic skin visible in both the saline and FGF2 groups. Reduced wound area in the SR-0379 group was sustained on days 6 and 13 (Fig. 4B). The skin wound was completely healed at day 19 with SR-0379 treatment, whereas the wound did not heal until day 24 with saline treatment (Fig. 4C).

To determine the utility of SR-0379 in a clinical situation, we finally evaluated whether the compound could accelerate wound healing in an acute infection wound model, as the presence of infection largely diminishes the wound-healing process. After creating full-thickness defects, *S. aureus* was inoculated. Treatment with SR-0379 (1 mg/ml) significantly reduced the unhealed wound size on days 8 and 15 compared to the saline and FGF2 groups (Fig. 5A, 5B). The effects of SR-0379 on wound healing were more potent than the effects of FGF2, which is currently a standard therapy (Fig. 4B, 5B). To determine the effect of SR-0379 on wound healing, granulation tissue formation was analyzed by subcutaneously implanting a paper disc (Fig. 5C). Granulation tissue weight was significantly increased by treatment with SR-0379 (100 µg/disc). To further evaluate the effect of SR-0379 on

**Table 1.** MICs of several compounds against *E. coli*, *P. aeruginosa* and *S. aureus*.

Compound	<i>E. coli</i> (ATCC25922)	<i>P. aeruginosa</i> (ATCC27853)	<i>S. aureus</i> (ATCC29213)
	MIC ( $\mu\text{g/ml}$ )		
AG30/5C	32	16/32	16/32
SR-0007	64	16/32	16/32
SR-0379	8	16/32	16
Tobramycin	0.25–1	0.25–1	0.12–1
Meropenem	0.008–0.06	0.25–1	0.03–0.12
Oxacillin	-	-	0.12–0.5

The scores indicate the MICs (mg/ml) for *E. coli*, *P. aeruginosa* and *S. aureus*. MICs represent the individual data from two independent experiments.  
doi:10.1371/journal.pone.0092597.t001

wound healing, collagen production and proliferation were measured using the incised wound rat model. The tensile strength after SR-0379 treatment (5  $\mu\text{g}$ ) was significantly increased compared to saline treatment. Treatment with SR-0379 induced granulation tissue formation and collagen production, which may accelerate wound healing.

Collagen gel assay is a conventional method to investigate cell behavior that more closely resembles cell behavior *in vivo*. As shown in Figure 2D, the diameter of the collagen gel containing went down by treatment of SR-0379. The promotion of the wound healing with SR-0379 was supported by the enhanced contraction *in vitro*.

## Discussion

Recently, wet dressing has been strongly recommended to accelerate the process of wound healing because epithelial cells and dermal fibroblasts proliferate well under wet conditions [13]. However, wounds under wet conditions present an ideal

environment for bacterial growth due to the presence of moisture and warmth. Wound infection has become one of the major risk factors in the delay of wound healing [14], although physicians take many precautions to prevent wound infection. Wound colonization is defined as the presence of multiplying microorganisms on the surface of a wound but with no associated clinical signs and symptoms of infection [15]. Recently, the term critical colonization has gained acceptance and is defined as the borderline of colonization and infection. As wound colonization is most frequently polymicrobial and involves numerous microorganisms that are potentially pathogenic, the diagnosis of clinical colonization is difficult for general physicians in a clinical setting. Recombinant growth factor proteins, such as FGF2 and PDGF, have been shown to stimulate ulcer-healing processes in clinical applications [16,17]. However, the wound might fail to be healed by these growth factors in the event of an infection, as these growth factors have no antibacterial properties. Therefore, a wound-healing drug with antibacterial properties would be ideal to avoid the risk of infection during wound care.

**Table 2.** *In vitro* activities of SR-0379 against Gram-positive and Gram-negative bacteria and fungi.

	Gram staining	Strain	MIC ( $\mu\text{g/ml}$ )		
			SR-0379	Chloramphenicol	
Bacteria	Aerobes	G(+)Bacilli	<i>Micrococcus luteus</i>	2	1
			<i>Bacillus subtilis</i>	2	4
		G(-)Bacilli	<i>Salmonella</i> Enteritidis	8	4
	<i>Salmonella</i> Typhimurium		8	4	
	<i>Acinetobacter baumannii</i>		8	16/32	
	Anaerobes		G(-)Bacilli	<i>Propionibacterium acnes</i>	16/32
		<i>Bacteroides fragilis</i>		32	1
<i>Fusobacterium nucleatum</i>		16/32		0.25	
Fungi		Strain	SR-0379	Amphotericin B	
		<i>Penicillium glabrum</i>	8/16	0.125	
		<i>Fusarium solani</i>	8	1	
		<i>Alternaria alternata</i>	32	1	
		<i>Trichophyton mentagrophytes</i>	32	0.125	
		<i>Trichophyton rubrum</i>	64	0.125	
	<i>Candida krusei</i>	32	2		

The scores indicate the MICs (mg/ml) for gram-positive and gram-negative bacteria and fungi. MICs represent the individual data from two independent experiments.  
NT: Not tested.


doi:10.1371/journal.pone.0092597.t002

**Table 3.** *In vitro* activities of SR-0379 against seven strains of drug-resistant bacteria.

Bacteria	Drug resistance	MIC ( $\mu\text{g/ml}$ )
<i>Pseudomonas aeruginosa</i>	Aminoglycoside-resistant	16
	Carbapenem-resistant	16–64
	Fluoroquinolone-resistant	16/64
<i>Staphylococcus aureus</i>	Methicillin-sensitive	32
	Methicillin-resistant (1)	32
	Methicillin-resistant (2)	32
<i>Acinetobacter baumannii</i>	Multidrug-resistant	16


MICs represent the individual data from two independent experiments.

doi:10.1371/journal.pone.0092597.t003



**Figure 2. Cellular function of SR-0379.** A) Effect of SR-0379 on NHDFs proliferation. NHDFs were treated with SR-0379 (1, 3 and 10  $\mu\text{g/ml}$ ) or FGF2 (0.1  $\mu\text{g/ml}$ ). N=4 per group. \* $P<0.05$  vs. control. B) The upper panel shows representative pictures of tube formation in a co-culture of HUVECs and NHDFs (Control, FGF2: 0.2  $\mu\text{g/ml}$ ) and SR-0379 (10  $\mu\text{g/ml}$ ). The lower panel shows the effects of SR-0379 on tube formation in a co-culture of HUVECs and NHDFs. N=5 per group. \* $P<0.05$ , \*\* $P<0.01$  vs. control. C) The upper panel shows representative pictures of the migration induced by FGF2 (0.1  $\mu\text{g/ml}$ ) and SR-0379 (10  $\mu\text{g/ml}$ ). The lower panel shows the effects of FGF2 (0.1  $\mu\text{g/ml}$ ) and SR-0379 (1 and 10  $\mu\text{g/ml}$ ) on migration. N=4 per group. \* $P<0.05$ , \*\* $P<0.01$  vs. control, # $P<0.01$  vs. SR-0379 (1  $\mu\text{g/ml}$ ). D) The upper panel shows representative pictures of the fibroblast-collagen-matrix contraction assay with FGF2 (0.3  $\mu\text{g/ml}$ ) and SR-0379 (1, 3, 10 and 30  $\mu\text{g/ml}$ ). The lower panel shows the effects of FGF2 (0.3  $\mu\text{g/ml}$ ) and SR-0379 (1, 3, 10 and 30  $\mu\text{g/ml}$ ) on fibroblast-collagen matrix contraction. N=3 per group. \* $P<0.05$ , \*\* $P<0.01$  vs. control. doi:10.1371/journal.pone.0092597.g002






**Figure 3. Activation of the PI3 kinase/AKT/mTOR pathway by SR-0379 in NHDFs.** A) Effects of SR-0379 on phosphorylated FAK (Tyr397 and Tyr925) and phosphorylated Akt (Ser473) as determined by Western blot. The cells were treated with SR-0379 (10 µg/ml) for 0, 5, 15 and 30 minutes or LL-37 (10 µg/ml) for 15 minutes. B) Effects of SR-0379 on phosphorylated FAK (Tyr397 and Tyr925) and phosphorylated Akt (Ser473) as determined by Western blot. The cells were treated with SR-0379 (0.1, 0.3, 1, 3 and 10 µg/ml) for 30 minutes. C, D) Effects of RGD peptide and wortmannin on the SR-0379-induced phosphorylation of FAK (Tyr397 and Tyr925) and Akt (Ser473) as determined by Western blot. The cells were preincubated with RGD peptide (30, 100 and 300 µM, an inhibitor of integrin-ligand interactions) (C) or wortmannin (100 nM) (D) for 30 minutes and were then treated with SR-0379 (10 µg/ml) for 30 minutes. E) Effects of RGD, wortmannin and rapamycin on the NHDFs proliferation stimulated by SR-0379. The cells were preincubated with RGD (1000 µM), wortmannin (100 nM) or rapamycin (1 nM) for 2 hours and then were treated with SR-0379 (10 µg/ml). N=3 per group. \*\*P<0.01 vs. control, ## P<0.01 vs. SR-0379 (10 µg/ml). F) Effects of Akt knockdown using siRNA on the NHDFs proliferation stimulated by SR-0379. The cells were pretreated with Akt si RNA or Control si RNA for 24 hours and then were treated with SR-0379 (1, 3 and 10 µg/ml). N=4 per group. \*\*P<0.01 vs. control si RNA, # P<0.05 vs. SR-0379 (1 µg/ml) treated with control siRNA. doi:10.1371/journal.pone.0092597.g003

Based on this idea, we developed AG30, an antibacterial peptide with angiogenic activity. Although our previous study demonstrated that AG30/5C is useful in the treatment of ulcers [8,9], cost and stability are problems for clinical applications. Therefore, in this study, we modified AG30/5C as a lead

compound to achieve 1) more stability upon exposure to serum, 2) lower cost, 3) wider antibacterial activity and 4) rapid wound healing. The initial analysis using the metabolites of AG30/5C revealed that a core sequence of 20 aa (MLKLIFLHRLKRMKRLKRRK; SR-0007) was enough to




**Figure 4. Effects of SR-0379 and FGF2 on full-thickness wound model with flap in diabetic rat model.** A) Representative pictures of skin flaps in the streptozotocin-induced diabetic model in the saline (control), SR-0379 (0.2 mg/ml) and FGF2 groups (0.06 mg/ml) on days 0, 6, 13 and 20. B) Quantification of the wound area is represented as a percentage of the initial wound area. N=6 per group. \*\*P<0.01 vs. control, ##P<0.01 vs. FGF2. C) Days to complete healing by the contraction of full-thickness skin flaps in the streptozotocin-induced diabetic model. doi:10.1371/journal.pone.0092597.g004

stimulate human umbilical vein endothelial cells (HUVECs) proliferation and tube formation at a level similar to AG30/5C. This smaller peptide led to a reduced cost of peptide synthesis. In the previous reports, the replacement with the D-form amino acid improved the proteolytic resistance of antimicrobial peptides [18]. For example, the D-amino acid variants of host defense peptide chicken cathelicidin-2 showed enhanced stability in human serum, and fully resistant to proteolysis by trypsin and bacterial proteases. The modifications increase the stability and lower cytotoxicity of the peptides without altering their antimicrobial potency. We also confirmed the degradation by the peptide bond cleavages in N-terminus of SR-0379, and the change from L-lysine to D-lysine (SR-0379) increased the resistance to serum. Importantly, SR-0379 displayed broader antibacterial activity than the original AG30 and SR-0007. The bactericidal action of antimicrobial peptides such as pexiganan is thought to result from irreversible membrane-disruptive damage [19] [20] [21]. Especially, from the mechanisms of antibacterial activity, SR-0379 exhibited the same MIC against drug-resistant strains, such as aminoglycoside-, carbapenem- and fluoroquinolone-resistant *P. aeruginosa* and MRSA and the multidrug-resistant *A. baumannii*. SR-0379 might be useful to prevent infection by these drug-resistant bacteria.

*In vitro* experiments with SR-0379 demonstrated the induction of proliferation, tube formation, migration and contraction. The closure of cutaneous wounds involves three processes: epithelization, connective-tissue deposition and contraction. In particular, contraction is one of the main factors contributing to epidermal

wound healing [22]. The fibroblast-collagen matrix contraction model provides a unique way to study mechanisms. Treatment with SR-0379 promoted contraction in this model, which corresponds to wound healing. The stimulatory effect of SR-0379 on the wound healing process was also confirmed by two *in vivo* wound-healing models. Furthermore, SR-0379 was able to induce angiogenesis and granulation tissue formation in the paper disc model and collagen production and proliferation in the incised wound rat model. These results support the potential use of SR-0379 in the wound-healing process. The ulcer model with infection is a unique model that is especially close to a clinical situation. Importantly, SR-0379 treatment resulted in rapid healing without infection compared to FGF2.

Although the multiple functions of antimicrobial peptides are well known, the mechanisms are still unclear. For example, LL-37 is often reported in the analysis of FPR2 (formerly known as FRPL1), the promiscuous Pertussis Toxin (PTX)-sensitive GPCR and the purinergic receptor P2X7 and in the transactivation of epidermal growth factor receptor (EGFR) [3]. The activation of EGFR in epithelial cells, endothelial cells and fibroblasts by LL-37 resulted in activation of the p38 MAPK, ERK1/2 MAPK, NFκB and PI3 kinase pathways. In contrast, although we also examined the contribution of P2X7 receptors to the effect of SR-0379, the specific antagonist of P2X7 (Brilliant Blue G) failed to inhibit the effects of SR-0379 (data not shown). SR-0379 also weakly activated EGFR. Interestingly, SR-0379 strongly activated FAK, while an integrin inhibitor (RGD peptide) blocked the Akt/



**Figure 5. Effects of SR-0379 and FGF2 on the full-thickness skin infected wound model.** A) Representative pictures of full-thickness skin flaps in uninfected, saline (control), SR-0379 (1 mg/ml) and FGF2 groups (0.125 mg/ml) on days 8 and 15. B) Quantification of the infected wound area is represented as a percentage of the initial wound area. N=5 per group. \*\*P<0.01 vs. control, ##P<0.01 vs. FGF2. C) Effects of SR-0379 (1, 10 and 100 µg/disc) on the healing of paper disc implantation in rats. N=4-5 per group. \*\*P<0.01 vs. control, ##P<0.05 vs. 1 µg/disc. D) Effects of SR-0379 (0.5 and 5 µg) on the healing of an experimental open wound in rats. N=3-4 per group. \*P<0.05 vs. control, #P<0.05 vs. 0.5 µg. doi:10.1371/journal.pone.0092597.g005

mTOR pathway. Downstream of FAK, SR-0379 also activated the PI3 kinase-Akt-mTOR pathway. As mTOR is known to regulate cell growth and survival by integrating nutrient and hormonal signals [10], an inhibitor, rapamycin, attenuated the proliferation induced by SR-0379 in human fibroblasts. The treatment of SR-0379 resulted in increase in cell proliferation of fibroblast, whereas Akt knockdown attenuated the SR-0379-induced cell proliferation. These results demonstrate the importance of Akt pathway in the effect of SR-0379.

We have successfully produced SR-0379 as a multifunctional (angiogenic and pro-fibrotic), potent antibacterial peptide with a broad spectrum, including aerobes and anaerobes, Gram-positive and Gram-negative species and drug-resistant and drug-sensitive bacteria and fungi. These properties occur via the activation of PI3 kinase-Akt-mTOR signaling and are useful in the stimulation of wound healing under wet conditions. Further modification of SR-0379 should yield an ideal compound for the treatment of diabetic ulcers, burns and other incurable ulcers. Currently, we plan to test SR-0379 in the treatment of patients with MRSA-positive diabetic and ischemic ulcers.

## Materials and Methods

### Analysis of the AG30/5C metabolites using MALDI-TOF/MS

Rat sera were collected from rats. AG30/5C was incubated in pooled rat serum at 37°C. Samples were collected before incubation, after 10 minutes of incubation and after 60 minutes of incubation and were precipitated by the addition of an equivalent amount of acetonitrile containing 0.1% trifluoroacetate. The samples were centrifuged, and the supernatants were purified using ZipTip m-C18 (Millipore, MA). Sample solution was mixed with matrix solution ( $\alpha$ -cyano 4-hydroxy cinnamic acid). The measurement sample for MALDI (0.4 µL) was applied on a MALDI target plate and dried, and the sequences of the AG30/5C metabolites were confirmed by MALDI-TOF/MS analysis (4700 Proteomics Analyzer, Applied Biosystems, CA).

### Serum stability assay

*In vitro* stability studies were performed by incubating the peptide with rat or human serum. Human sera (Pool of donors, 5 men and 5 women) were commercially purchased from KAC (Kyoto, Japan), which has been permitted only for experiment. We don't use the human biological specimens without the documented informed consent. Rat sera were collected from rats. The peptide (500 µg/ml) was added to serum (300 µL) and incubated at 37°C. A part of samples (90 µL) were taken, and the proteins were precipitated with acetonitrile containing 0.1% trifluoroacetate (200 µL). The precipitate was separated by centrifugation. The supernatants were analyzed by high-performance liquid chromatography (HPLC).

### Proliferation, tube formation, cell migration and contraction assays

HUVECs, NHDFs and NHEKs were purchased from Kurabo (Osaka, Japan). The endothelial cells were maintained in HuMedia EB2 and the fibroblasts were maintained in Medium 106S. Both media were supplemented with 1% fetal bovine serum (FBS) as described previously [9]. The epidermal keratinocytes were maintained in HuMedia KB2. Cells were incubated at 37°C in a humidified atmosphere of 95% air/5% CO<sub>2</sub> with exchange of medium every 2 days. HUVECs were cultured in 96-well plates at a density of 10,000 cells/well and incubated for 48 hours at 37°C with AG30/5C or FGF2 (recombinant human FGF basic, R&D systems, Inc., Minneapolis, MN). The proliferation of HUVECs, NHDFs and NHEKs was analyzed using a WST-1 assay (Dojindo, Kumamoto, Japan). Tubule formation assay has recently been developed in which endothelial cells are co-cultured with fibroblasts. An angiogenesis assay kit (Kurabo, Osaka Japan) was used according to the manufacturer's instructions. Various concentrations of peptides or FGF2 were added to the medium. After 11 days, the cells were incubated with diluted primary antibody (mouse anti-human CD31, 1:4,000) for 1 hour at 37°C and diluted secondary antibody (goat anti-mouse IgG alkaline phosphatase-conjugated antibody, 1:500) for 1 hour at 37°C; visualization was achieved with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT). The tube-like structures were measured in terms of total tube length with the software (Angiogenesis Image Analyzer, Kurabo, Osaka Japan). Cell migration was evaluated using an Oris cell migration assay kit (Platypus Technologies, LLC., Madison, WI) according to the manufacturer's instructions. Briefly, the assay utilizes cell-seeding stoppers to restrict cell seeding to the outer annular regions of the wells. Removal of the stoppers reveals a 2-mm diameter unseeded region, the migration zone, into which the seeded cells migrate. The number of cells that migrated into the detection zone was measured using a plate reader. Cellular collagen gel contraction assays were performed as previously described [23] [24]. A solution of collagen and NHDFs ( $2 \times 10^6$  cells/ml) was added to a 24-well plate at 37°C for 1 hour, and medium supplemented with DMEM containing 10% FBS was then added. The cells were cultured for 24 hours. The culture medium was removed, and DMEM (serum-free) containing SR-0379 or FGF2 was added. The cell-embedded matrix was released from the culture dish surface. At each time point, the lattices were digitally photographed from a fixed distance, and their areas were calculated using image analysis software. In the proliferation assay of fibroblast, RGD peptide, Wotmannin, Akt inhibitor IV and Genistein were obtained from Sigma-Aldrich (St. Louis, MO). Rapamycin was obtained from Funakoshi Co., Ltd. (Tokyo, Japan). Akt siRNA I (#6211) and control siRNA I (#6568) were obtained from Cell Signaling (Boston, MA).

NHDFs were plated at a density of 5000 cells per well in 96-well culture plates in the corresponding culture media without antibiotics one day prior to transfection. Lipofectamine RNAi-MAX was purchased from Invitrogen. The lipofectamin (2 µL) was gently added to 100 µL medium and the mixture was incubated for 20 minutes at room temperature. The Akt or Control siRNA was added to the mixture and was incubated for 5 minutes. Transfection complexes were added to each well. NHDFs were incubated for 24 hours at 37°C in a CO<sub>2</sub> incubator and then SR-0379 (10 µg/ml) was added. NHDFs proliferation was analyzed using a WST-1 assay.

### Measurement of MICs against Bacteria and Fungi

Antimicrobial activity of the peptides was evaluated against *Escherichia coli* JCM 5491, *Pseudomonas aeruginosa* JCM 6119, *Staphylococcus aureus* JCM2874, *Salmonella* Typhimurium JCM1652, *Acinetobacter baumannii* JCM6841, *Bacteroides fragilis* JCM11019, *Fusobacterium nucleatum* JCM11025, *Penicillium glabrum* JCM22534, *Fusarium solani* JCM11383, *Alternaria alternata* JCM5800 (RIKEN, A research institution for basic and applied science in Japan), *Micrococcus luteus* NBRC13867, *Bacillus subtilis* NBRC3134, *Propionibacterium acnes* NBRC107605, *Trichophyton mentagrophytes* NBRC6124, *Trichophyton rubrum* NBRC9185, *Candida krusei* NBRC1395 (National Institute of Technology and Evaluation, Tokyo, Japan), *Salmonella* Enteritidis IID604 (The Institute of Medical Science, The University of Tokyo, Tokyo, Japan). Additionally, the clinical isolates (Drug-sensitive/resistant *Pseudomonas aeruginosa* and *Staphylococcus aureus*, Osaka University Hospital) and multidrug-resistant *Acinetobacter baumannii* (ATCC BAA-1605) were used. The MICs (expressed as µg/ml) of AG30/5C, SR-0007 and SR-0379 were determined by the broth microdilution method as previously described [8,9]. Serial two-fold dilutions of peptide were added to 0.1 ml of medium containing each type of bacteria and fungi at concentrations of  $0.4 \times 10^4 - 5 \times 10^4$  CFU/ml. The plates were incubated at 37°C with vigorous shaking for 24 or 48 hours. The MICs were determined as the lowest concentrations of peptide that inhibited visible bacterial growth.

### Western blot analysis

Protein extracts (15 µg) were resolved by 10% SDS-PAGE and were then transferred to nitrocellulose membrane. Western blotting was performed. Phospho FAK (Tyr397), Akt, phospho Akt (Ser 473), mTOR, phospho mTOR (Ser2448) and  $\alpha$ -Tubulin antibodies were obtained from Cell Signaling (Boston, MA). FAK antibody was obtained from Millipore (Billerica, MA). Phospho FAK (Tyr925) antibody was obtained from Abcam (Cambridge, MA).

### Real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis and ELISA

Expression of the human IL-8 mRNA was measured using real-time reverse transcription polymerase chain reaction (RT-PCR). Total RNA was extracted from the tissue samples using ISOGEN reagent (NIPPON GENE, Toyama, Japan). Complementary DNA (cDNA) was synthesized using the Thermo Script RT-PCR System (Invitrogen, Carlsbad, CA). Relative gene-copy numbers for IL-8 mRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were determined by real-time RT-PCR using TaqMan Gene Expression Assays (IL-8: Hs00174103\_m1; GAPDH: 4352934). Absolute gene-copy numbers were normalized to GAPDH using a standard curve.

The cell free culture supernatants were harvested after treatment of SR-0379 (1, 3 and 10 µg/ml) at 24, 48 and 72 hours.

The amount of IL-8 was measured by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.

#### Effect of SR-0379 on wound healing in a streptozotocin-induced diabetic model

This experimental protocol was approved by the committee for ethics in animal studies of AnGes MG. Male HWY/Slc rats (7 weeks) were given a single intravenous injection of 65 mg/kg streptozotocin (STZ, Sigma-Aldrich, St. Louis, MO), and whole-blood glucose was monitored 24 hours later. This strain is hairless in adult and suitable for wound healing model. The glucose level criterion for diabetes was set at 300 mg/dl. STZ-induced diabetic rats were anesthetized. The square flap (1.73 cm × 1.73 cm) was made in the back of rats. In the center of the flap, the square wound (1.41 cm × 1.41 cm) with full-thickness defect was made (area per wound; 2 cm<sup>2</sup>). In the flap model, skin was cut in three directions of square wound to partially block the blood flow to wound. SR-0379 (0.2 mg/ml, 50 μl), FGF2 (0.06 mg/ml, 50 μl) or saline (control) was administered to each wound (each time point from day 0 to 28). Dressings (Perme-roll, Nitto Denko, Japan) were applied to the wounds. We took a picture of wound with scale every time and calculated the size of scanned image using software (<http://hp.vector.co.jp/authors/VA004392/Download.htm#lenara>).

#### Effect of SR-0379 on wound healing in a cyclophosphamide-induced immunodeficient infection model

Male HWY/Slc rats (7 weeks) were given a single intravenous injection of 100 mg/kg cyclophosphamide (CPA, Wako Pure Chemical Industries, Ltd., Osaka, Japan) and were anesthetized for the preparation of a full-thickness skin flap 24 hours later. CPA-treated rats with white blood cell counts lower than 5,000 were used. The bacteria (*S. aureus*, 1 × 10<sup>5</sup> CFU/ml) was applied to each wound on days 0, 1, 2 and 3. SR-0379 (1 mg/ml, 50 μl), FGF2 (125 μg/ml, 50 μl) and saline (control, 50 μl) were administered to the wound at time points on days 0 to 27. Dressings (Perme-roll, Nitto Denko, Japan) were applied to the wounds. Healing size was evaluated by photographing the wound area at a close and fixed distance. The remaining unhealed wound size was measured from the image.

#### Evaluation of granulation tissue formation in a paper disc implantation model

Granulation tissue formation was determined as described previously [25]. A paper disc containing saline or SR-0379 (1, 10 and 100 μg) was implanted into the subcutaneous tissue on the backs of 9-week-old Crl:CD(SD) rats under anesthesia. Four or five rats were used for each experimental condition. The paper disc was removed on day 8 and the granulation tissue around the paper disc was weighed after the removal of absorbed fluids with paper wipe.

#### Evaluation of collagen production and proliferation in the incised wound rat model

The dermises of Crl:CD(SD) rats (7 weeks) were incised under anesthesia. In the back of rats, we cut the skin (30 mm) and sutured 3 points (Nylon thread, Natsume Seisakusho Co., Ltd., Tokyo, Japan). SR-0379 (0.5 and 5 μg per day) was topically

administered in sutured wound one a day for 5 days, and during the period the suture was removed at day 3. At day 6, extracted skin was fixed in one side and pulled in another side. The tension was monitored until the opening of sutured wound. In this evaluation, the increase in tension reflects the strength of sutured wound.

#### Statistical analysis

All values are expressed as the means + SEM. Analysis of variance and a subsequent Fisher's Least Significant Difference test were used to determine the significance of differences in multiple comparisons.

#### Supporting Information

**File S1 Supporting figures S1–S4.** Figure S1, MALDI-TOF MS analysis. A) Major metabolites of AG30/5C determined by MALDI-TOF MS. Parent compound (AG30/5C) was incubated with rat serum *in vitro* for 10 minutes and 60 minutes. The metabolites were identified by the comparison with that from preincubation. Figure S2, Effect of SR-0379 on cell proliferation. Normal Human Epidermal Keratinocytes (NHEKs) were treated with SR-0379 (1, 3 and 10 μg/ml). The results were shown as percent increase compared with control (no treatment). N = 3 per group. \*P<0.05 vs. control. Figure S3, Effect of Akt pathway on SR-0379-induced cell proliferation. A) Knockdown of Akt expression by siRNA was confirmed with western blot analysis anti-Akt antibody and anti-α-tubulin antibody. The sample was extracted from NHDFs with no treatment (NT), non-target siRNA (C: control) and Akt siRNA. B) Effects of Akt inhibitor on NHDFs proliferation stimulated by SR-0379. The cells were preincubated with Akt inhibitor IV (1 μM) for 1 hour and then were treated with SR-0379 (1, 3 and 10 μg/ml). N = 3 per group. \*P<0.05 vs. control, \*\*P<0.01 vs. control, ## P<0.01 vs. SR-0379 (1 μg/ml), †† P<0.01 vs. SR-0379 (3 μg/ml), ‡‡ P<0.01 vs. SR-0379 (10 μg/ml). Figure S4, Up-regulation of interleukin-8 (IL-8) induced by treatment of SR-0379. A) IL-8 mRNA expression was quantified by real time PCR and shown as a relative expression compared with that of GAPDH mRNA. NHDFs were treated with SR-0379 (10 μg/ml) for 24 hours. Effects of Wortmannin (PI3kinase inhibitor, 100 nM) and Genistein (Tyrosine-specific protein kinase inhibitor, 100 nM) on SR-0379-induced IL-8 mRNA expression. N = 3 per group. \*P<0.05 vs. control, \*\*P<0.01 vs. control, ## P<0.01 vs. SR-0379 (no inhibitor). B) IL-8 levels in culture supernatants from NHDF were measured by ELISA at 24, 48 and 72 hours after treatment. NHDFs were treated with SR-0379 (1, 3 and 10 μg/ml) for 72 hours. N = 2. (PDF)

#### Acknowledgments

We thank Ms. Ryoko Sata and Mr. Shintaro Komaba for their technical assistance.

#### Author Contributions

Conceived and designed the experiments: HN KT YK RM. Performed the experiments: HT HN AT YS T. Kanamori T. Kaga NT. Analyzed the data: HT AT T. Kanamori. Contributed reagents/materials/analysis tools: HT AT T. Kaga. Wrote the paper: HT HN.



## References

- Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, et al. (1985) Defensins. Natural peptide antibiotics of human neutrophils. *J Clin Invest* 76: 1427–1435.
- Wang G, Li X, Wang Z (2009) APD2: the updated antimicrobial peptide database and its application in peptide design. *Nucleic Acids Res. England*. pp. D933–937.
- Vandamme D, Landuyt B, Luyten W, Schoofs L (2012) A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell Immunol* 280: 22–35.
- Gordon YJ, Romanowski EG, McDermott AM (2005) A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. *Curr Eye Res. England*. pp. 505–515.
- Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol. United States*. pp. 1551–1557.
- Fox MA, Thwaite JE, Ulaeto DO, Atkins TP, Atkins HS (2012) Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin II. *Peptides. United States: Crown* 2012. Published by Elsevier Inc. pp. 197–205.
- Won A, Khan M, Gustin S, Akpawu A, Seebun D, et al. (2011) Investigating the effects of L- to D-amino acid substitution and deamidation on the activity and membrane interactions of antimicrobial peptide anoplins. *Biochim Biophys Acta. Netherlands: 2010 Elsevier B.V.* pp. 1592–1600.
- Nishikawa T, Nakagami H, Maeda A, Morishita R, Miyazaki N, et al. (2009) Development of a novel antimicrobial peptide, AG-30, with angiogenic properties. *J Cell Mol Med. England*. pp. 535–546.
- Nakagami H, Nishikawa T, Tamura N, Maeda A, Hibino H, et al. (2012) Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents. *J Cell Mol Med* 16: 1629–1639.
- Squarize CH, Castilho RM, Bugge TH, Gutkind JS (2010) Accelerated wound healing by mTOR activation in genetically defined mouse models. *PLoS One* 5: e10643.
- Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, et al. (1999) In vitro antibacterial properties of pexiganan, an analog of magainin. *Antimicrob Agents Chemother* 43: 782–788.
- Gottler LM, Ramamoorthy A (2009) Structure, membrane orientation, mechanism, and function of pexiganan—a highly potent antimicrobial peptide designed from magainin. *Biochim Biophys Acta. Netherlands*. pp. 1680–1686.
- Dyson M, Young S, Pendle CL, Webster DF, Lang SM (1988) Comparison of the effects of moist and dry conditions on dermal repair. *J Invest Dermatol* 91: 434–439.
- Woo KY, Coutts PM, Sibbald RG (2012) A randomized controlled trial to evaluate an antimicrobial dressing with silver alginate powder for the management of chronic wounds exhibiting signs of critical colonization. *Adv Skin Wound Care. United States*. pp. 503–508.
- Edwards R, Harding KG (2004) Bacteria and wound healing. *Curr Opin Infect Dis. United States*. pp. 91–96.
- Akita S, Akino K, Imaizumi T, Tanaka K, Anraku K, et al. (2006) The quality of pediatric burn scars is improved by early administration of basic fibroblast growth factor. *J Burn Care Res. United States*. pp. 333–338.
- Wieman TJ, Smiell JM, Su Y (1998) Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. *Diabetes Care* 21: 822–827.
- Molhoek EM, van Dijk A, Veldhuizen EJ, Haagsman HP, Bikker FJ (2011) Improved proteolytic stability of chicken cathelicidin-2 derived peptides by D-amino acid substitutions and cyclization. *Peptides* 32: 875–880.
- Boman HG (1995) Peptide antibiotics and their role in innate immunity. *Annu Rev Immunol* 13: 61–92.
- Hancock RE (1997) Peptide antibiotics. *Lancet* 349: 418–422.
- Jacob L, Zasloff M (1994) Potential therapeutic applications of magainins and other antimicrobial agents of animal origin. *Ciba Found Symp* 186: 197–216; discussion 216–123.
- Kao HK, Chen B, Murphy GF, Li Q, Orgill DP, et al. (2011) Peripheral blood fibrocytes: enhancement of wound healing by cell proliferation, re-epithelialization, contraction, and angiogenesis. *Ann Surg* 254: 1066–1074.
- Grinnell F (2000) Fibroblast-collagen-matrix contraction: growth-factor signaling and mechanical loading. *Trends Cell Biol. England*. pp. 362–365.
- Carlson MA, Longaker MT (2004) The fibroblast-populated collagen matrix as a model of wound healing: a review of the evidence. *Wound Repair Regen. United States*. pp. 134–147.
- Okumura M, Okuda T, Okamoto T, Nakamura T, Yajima M (1996) Enhanced angiogenesis and granulation tissue formation by basic fibroblast growth factor in healing-impaired animals. *Arzneimittelforschung* 46: 1021–1026.

# Development of LC-MS/MS Quantification of the Novel Antimicrobial Peptide, SR-0379, and its Pharmacokinetics in Rats

Hideki Tomioka<sup>1,2</sup>, Hironori Nakagami<sup>3\*</sup>, Tomokazu Sano<sup>4</sup>, Kazuaki Takafuji<sup>5</sup>, Seiji Takashima<sup>5</sup>, Yasufumi Kaneda<sup>6</sup> and Ryuichi Morishita<sup>1\*</sup>

<sup>1</sup>Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; <sup>2</sup>AnGes MG, Inc. 7-7-15 Saito Bio-Incubator, Ibaraki, Osaka 567-0085, Japan; <sup>3</sup>Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, 2-1 Yamada-oka, Suita, Osaka 565-0871, Japan; <sup>4</sup>Drug Disposition Research Group, Contract Research Department, ADME & Tox. Research Institute, Sekisui Medical Co., Ltd., 2117 Muramatsu, Tokai, Ibaraki, 319-1182, Japan; <sup>5</sup>Center for Medical Research and Education, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; <sup>6</sup>Division of Gene Therapy Science, Osaka University Graduate School of Medicine, 2-1 Yamada-oka, Suita, Osaka 565-0871, Japan

**Abstract:** During the preclinical study of the original functional peptide, SR-0379, a sensitive liquid chromatography-tandem mass spectrometry method was newly developed to study the pharmacokinetics of SR-0379 in rat plasma and subcutaneous tissue samples. Although SR-0379 was unstable in the rat plasma and subcutaneous tissue samples, pretreatment with EDTA and phosphoric acid (4 %) inhibited its degradation. The lower limits of quantification (LLOQ) for SR-0379 were fully validated as 5 ng/ml in plasma and 5 ng/g in tissue with acceptable linearity, intra- and inter-assay precisions, and accuracy. Measurement of SR-0379 concentration in plasma after intravenous injection *via* LC-MS/MS yields plasma concentration-time curves ( $AUC_{0-\infty}$ ) with areas of 667 ng•min/ml and an elimination half-life ( $t_{1/2}$ ) of 4.8 min. The concentration of SR-0379 in the subcutaneous tissue samples was 13.1 µg/g tissue at 30 minutes after a single dermal application (1 mg/ml, 50 µl) to a full-thickness excisional wound. Here, a highly sensitive and specific LC-MS/MS assay with a lower limit of quantification of 5 ng/ml was developed and validated to quantify SR-0379 in rat plasma. This method is useful for pharmacokinetic studies of the peptide drugs in rats.

**Keywords:** LC-MS/MS, pharmacokinetics, plasma, quantitation, subcutaneous tissue.

## INTRODUCTION

While screening of the functional genes for angiogenic molecules *via in silico* analysis, we have developed a novel small, angiogenic peptide with thirty amino acids, named as AG30 [1, 2]. From AG30, we further developed a potent angiogenic peptide with anti-microbial activity, named as SR-0379, which has twenty amino acids (under submission). Because both of anti-microbial and angiogenic actions are required in the wound healing process, SR-0379 might be an effective therapeutic agent to treat the wounds such as decubitus ulcer, diabetic ulcer, and burn ulcers.

Recently, functional peptides and proteins have been considered as potential drugs [3-5]. Bioassays, immunoassays and isotope tracer techniques have been used to evaluate the pharmacokinetics of peptides and proteins [6]. Immunoassays such as ELISA are unable to distinguish such compounds from their metabolites, which is the primary disad-

vantage of these methods [7]. The total radioactivity detected using an isotope tracer technique is not indicative of the parent compound concentration in biological samples [8]. Mass spectrometry-based technologies can provide many benefits over these methods [9]. The quantitative analysis of peptides and proteins *via* liquid chromatography/mass spectrometry (LC/MS) might be difficult; however, LC/MS methods that utilize a triple quadrupole, ion trap, and quadrupole time-of-flight (Q-ToF) were recently used to quantify peptides [10-12]. Based on these techniques, we have newly developed a sensitive method for determining bioactive peptides in rat plasma and tissues.

## MATERIALS AND METHODS

### Reagents

Synthetic SR-0379 was purchased from ILS, Inc. (Tokyo, Japan). An internal standard (purity>99%) containing L-Leucine-<sup>13</sup>C<sub>6</sub> and <sup>15</sup>N was purchased from Sigma-Aldrich (Hokkaido, Japan) and used without further purification. All organic solvents were of LC/MS grade and were obtained from Kanto Chemical Co., Inc. (Tokyo, Japan) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan). HPLC grade water was obtained using a water purification system (Auto pure WR600G, Yamato Scientific Co., Ltd, Tokyo, Japan).

\*Address correspondence to these authors at the Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development; Tel/Fax: +81-6-6879-4142; E-mail: [nakagami@gts.med.osaka-u.ac.jp](mailto:nakagami@gts.med.osaka-u.ac.jp) and Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, 565-0871, Japan; Tel: +81-6-6879-3406; Fax: +81-6-6879-3409; E-mail: [morishit@cgt.med.osaka-u.ac.jp](mailto:morishit@cgt.med.osaka-u.ac.jp)